Characterization of Genetic Defects of Hemophilia B of Chinese Origin

Summary

To define the precise genetic defects of hemophilia B of Chinese origin, we have used the polymerase chain reaction (PCR) combined with direct sequencing to analyze the amplified DNA fragments containing the entire coding regions and their flanking introns of the factor IX gene from 6 affected individuals. Among these patients, two are siblings with normal factor IX antigen level (CRM⁺) yet reduced factor IX clotting activity (28%). Analysis of their factor IX genes revealed a G to A transition at nucleotide residue 10394, which causes substitution of an arginine for a glycine at amino acid residue 48. This is a novel mutation which resides in the first EGF-like domain of factor IX. Studies of two other hemophilia B patients with CRM^r phenotypes (factor IX antigen level <35%, and clotting activity <1%), demonstrated a distinct mutation in each individual's factor IX gene. In one case, a guanine to adenine (residue 6365) transition results in replacement of arginine by glutamine at the –4 codon of the propeptide of factor IX. In the other, thymine at 6442 was mutated to cytosine which causes an arginine for cysteine substitution at residue 23. We have also characterized 2 discrete CRM^- patients. Both exhibited an identical mutation at nucleotide residue 6460 which generates a translation termination codon (CGA to TGA) at the 29th amino acid. The mutation created a new NlaIII restriction enzyme site which could be used to identify this variant.

• References

• 1 Purrello M, Alhadeff B, Esposito D, Szabo P, Rocchi M, Truett M, Masiarz F, Siniscalco M. The human genes of hemophilia A and hemophilia B flank the X chromosome fragile site at Xq27.3. EMBO J 1985; 4: 725-9
• 2 Brownlee GG. Haemophilia B: a review of patient defects, diagnosis with gene probes and prospects for gene therapy. In: Recent Advances in Haematology.. Hoffbrand AV. (ed) Churchill Livinstone, Edinburgh: 1988. vol. 5 pp 251-64
• 3 Gianelli F, Green PM, High KA, Lozirer JN, Lillicrap DP, Ludwig M, Olek K, Reitsma PH, Goossens M, Yoshioka A, Sommer S, Brownlee GG. Haemophilia B. database of point mutations and short additions and deletions. Nucleic Acids Res 1990; 1 8 4053-9
• 4 Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K. Nucleotide sequence of the gene for human factor IX (anti-haemophilic factor IX). Biochemistry 1985; 24: 3736-50
• 5 Anson DS, Choo KH, Rees DJ, Giannelli F, Gould K, Huddleston JA, Brownlee GG. Gene structure of human anti-haemophilic factor. EMBO J 1984; 3: 1053-64
• 6 Kurachi K, Davie EW. Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci USA 1982; 79: 6461-4
• 7 Haye M, de la Salle H, Schamber F, Balland A, Kohli V, Findeli A, Toltoshev T, Lecocq JP. Isolation of a human antihaemophilic factor IX cDNA clone using a unique 52-base synthetic oligonucleotide probe deduced from the amino acid sequence of bovine factor IX. Nucleic Acids Res 1983; 11: 2525-34
• 8 McGraw RA, Davis LM, Noyes CM, Lundblad RL, Roberts HR, Graham JB, Stafford DW. Evidence for a prevalent dimorphism in the activation peptide of human factor IX. Proc Natl Acad Sci USA 1985; b 82: 2847-51
• 9 Fujikawa K, Thompson A, Legaz M, Meyer R, Davie EW. Isolation and characterization of bovine factor IX (Christmas factor). Biochemistry 1973; 12: 4938-45
• 10 Di Scipio RG, Kurachi K, Davie EW. Activation of human factor IX (Christmas factor). J Clin Invest 1978; 61: 1528-37
• 11 Osterud B, Flengsrud R. Purification and some characteristics of the coagulation factor IX from human plasma. Biochem J 1975; 145: 469-74
• 12 Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res 1976; 3: 2303-8
• 13 Saiki RK, Scharf S, Faloona F, Mullis KB, Hort GT, Erlich HA, Arnheim N. Enzymatic amplification of β-globin genomic sequence and restriction site analysis for diagnosis of sickle cell anemia. Science 1985; 230: 1350-4
• 14 Lozier JN, Monroe DM, Stanfield-Oakley S, Lin SW, Smith KJ, Roberts HR, High KA. Factor IX New London: Substitution of proline for glutamine at position 50 causes severe hemophilia B. Blood 1990; 75: 1097-14
• 15 Mihovilovic M, Lee JE. An efficient method for sequencing PCR amplified DNA. Biotechniques 1989; 7: 14-6
• 16 Sanger F, Nicklen S, Couson R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-7
• 17 Cooke RM, Wilkinson AJ, Baron M, Pastore A, Tappin MJ, Cambell ID, Gregory H, Sheard B. The solution structure of human epidermal growth factor. Nature 1987; 327: 339-41
• 18 Bentley AK, Rees DJG, Rizza C, Brownlee GG. Defective propeptide processing of blood clotting factor IX caused by mutation of arginine to glutamine at position –4. Cell 1986; 45: 305-7
• 19 Ware J, Diuguid DL, Liebman HA, Rabiet MJ, Kasper CK, Furie BC, Furie B, Stafford DW. Factor IX San Dimas. J Biol Chem 1987; 264: 11401
• 20 Sugimoto M, Miyata T, Kawabata S, Yoshioka A, Fukui H, Iwanaga S. Factor IX Kawachinagano: impaired function of the Gla-domain caused by attached propeptide region due to substitution of arginine by glutamine at position –4. Br J Haematol 1989; 72: 216-21
• 21 Smith KJ, Thompson AR, McMullen BA, Frazier D, Lin SW, Stafford DW, Kiesel W, Thibideau SA, Chen SH, Smith L. Carrier testing in hemophilia B with an immunoassay which distinguishes a prevalent factor IX dimorphism. Blood 1987; 70: 1006-13
• 22 Thompson AR, Chen SH, Smith KJ. Role of an immunoassay-detected polymorphism of factor IX in diagnosing hemophilia B carriers. Blood 1987; 70 (Suppl. 1) 382a
• 23 Arvella B, Oberle I, Vincent A, Hofker MH, Pearson PL, Mandal JL. Genetic mapping of the Xq27-q28 region: New RFLP markers useful for diagnostic applications in fragile-X and hemophilia B families. Am J Hum Genet 1988; 42: 380-9
• 24 Summers KM. DNA polymorphism in human populations. Ann Hum Biol 1987; 14: 203-17
• 25 Scott CR, Chen SH, Schoof J, Kurachi K. Hemophilia B: population differences in RFPL frequencies useful for carrier detection. Am J Hum Genet 1987; 41: A262 (Abstr)
• 26 Freedenberg DL, Chen SH, Kurachi K, Scott CR. MspI polymorphic site within the factor IX gene. Hum Genet 1987; 76: 262-4
• 27 Davis LM, McGraw RA, Ware JL, Roberts HR, Stafford DW. Factor IX Alabama: A point mutation in a clotting protein results in hemophilia B. Blood 1987; 69: 140-3
• 28 Jones ME, Griffith MJ, Monroe DM, Roberts HR, Lentz BR. Comparison of lipid binding and kinetic properties of normal, variant, and gamma carboxyglutamic acid modified factor IX and factor IXa. Biochemistry 1985; 24: 8064-8
• 29 Soriano-Garcia M, Park CH, Tulinsky A, Ravichandran KG, Skrzypczak-Jankun E. Structure of Ca²⁺ prothrombin fragment 1 including the conformation of the Gla domain. Biochemistry 1989; 28: 6805-10